All Trials

An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced NSCLC who have progressed after standard therapies (including prior immunotherapy and platinum-based chemotherapy, or targeted therapy if actionable mutations are present) to receive HLX43, an investigational anti-PD-L1 antibody-drug conjugate linked to a topoisomerase I inhibitor, given intravenously every 3 weeks at two dose levels. Key exclusions include prior topoisomerase I inhibitor exposure, active CNS disease, or small cell/neuroendocrine/sarcomatoid histology.

ClinicalTrials.gov ID: NCT06907615

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung03)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Adults with stage IV, non-squamous, metastatic NSCLC expressing PD-L1 (≥1%) without EGFR, ALK, or ROS1 mutations are randomized to receive either rilvegostomig—a bispecific PD-1/TIGIT antibody—or pembrolizumab, each in combination with platinum+pemetrexed chemotherapy, as first-line treatment. Prior immunotherapy is not permitted; patients with symptomatic brain metastases or active autoimmune disease are excluded.

ClinicalTrials.gov ID: NCT06627647

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Metastatic NSCLC With PD-L1 TPS ≥50%

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with newly diagnosed, metastatic KRAS G12C-mutant NSCLC and high PD-L1 expression (TPS ≥50%), randomizing them to pembrolizumab plus either MK-1084—a selective KRAS G12C inhibitor—or placebo as first-line treatment. Key exclusions include prior systemic therapy for metastatic disease, active CNS disease, and certain comorbidities.

ClinicalTrials.gov ID: NCT06345729

A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10).

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated, locally advanced or metastatic non-squamous NSCLC, high PD-L1 expression (TC ≥ 50%), and no EGFR/ALK/ROS1 alterations, randomizing to either datopotamab deruxtecan (a TROP2-directed ADC) plus rilvegostomig (a bispecific PD-1/TIGIT antibody), rilvegostomig alone, or pembrolizumab monotherapy as first-line therapy. Eligible patients must have ECOG 0-1 and no prior systemic therapy for advanced disease.

ClinicalTrials.gov ID: NCT06357533

A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Uncommon EGFR Mutations Only)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring uncommon EGFR mutations (excluding those with active CNS metastases or prior EGFR TKI use) to receive sutetinib, an investigational irreversible EGFR tyrosine kinase inhibitor, given orally in 28-day cycles.

ClinicalTrials.gov ID: NCT06010329

A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody) in Combination With Cemiplimab (Anti-PD-1 Antibody) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 ≥50%

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic NSCLC (stage IIIB/C or IV), PD-L1 ≥50%, who are current or former smokers and lack actionable driver mutations, comparing cemiplimab (anti-PD-1) monotherapy to its combination with fianlimab, an investigational anti-LAG-3 antibody. Never-smokers and those with EGFR, ALK, or ROS1 alterations are excluded.

ClinicalTrials.gov ID: NCT05785767

A Randomized, Open-label, Phase 3 Study of MK-2870 vs. Platinum Doublets in Participants With EGFR-mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced, EGFR-mutated, non-squamous NSCLC who have progressed after prior EGFR TKI therapy, randomizing them to either sacituzumab tirumotecan (a TROP2-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor) or standard platinum-based chemotherapy with pemetrexed and carboplatin.

ClinicalTrials.gov ID: NCT06305754

A Phase II/III, Multisite, Randomized Master Protocol for a Global Trial of BNT327 in Combination With Chemotherapy and Other Investigational Agents in First-line Non-small Cell Lung Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Eligible patients are adults with advanced (stage IIIB/C or IV) non-small cell lung cancer lacking EGFR/ALK alterations, randomized to receive either BNT327—a bispecific antibody targeting PD-L1 and VEGF-A—in combination with chemotherapy, or standard pembrolizumab plus chemotherapy as first-line treatment.

ClinicalTrials.gov ID: NCT06712316

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion or other uncommon EGFR mutations (excluding C797S), including those previously treated with ex20ins agents, untreated, or with active brain metastases, to receive zipalertinib, an oral, irreversible EGFR tyrosine kinase inhibitor selective for mutant EGFR. All patients receive zipalertinib monotherapy until progression or withdrawal.

ClinicalTrials.gov ID: NCT05967689

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic nonsquamous NSCLC with EGFR mutations or other actionable genomic alterations who have progressed after EGFR TKI and platinum chemotherapy, randomizing them to sacituzumab tirumotecan (an anti-TROP2 antibody-drug conjugate with a topoisomerase I inhibitor payload) versus standard chemotherapy (docetaxel or pemetrexed). Eligible patients must have good performance status (ECOG 0-1).

ClinicalTrials.gov ID: NCT06074588